常染色体显性多囊肾病肾脏结局预测:综合生物标志物分析
本研究在596例ADPKD患者中评估了13种生物标志物加入传统危险因素后的预测价值,随访显示尿白蛋白/肌酐、尿单核细胞趋化蛋白-1/肌酐和血清和肽素可独立预测eGFR斜率、快速进展及复合肾脏终点,并在外部验证队列(N=144)中得以确认。
要点
- 尿白蛋白/肌酐、尿MCP-1/肌酐和血清和肽素独立预测ADPKD肾脏结局。
- 联合生物标志物可提升快速进展和复合终点的预测区分度。
- 预测价值在早期疾病和MIC 1C亚组中仍稳健。
核心结论
- 将尿白蛋白/肌酐、尿MCP-1/肌酐和血清和肽素纳入ADPKD风险分层工具可改善风险预测。
研究设计与样本
- 研究纳入596例来自Developing Intervention Strategies to Halt Progression of ADPKD队列的患者,要求至少2次eGFR测量且随访≥1年。
- 评估将13种预后生物标志物加入已建立风险因素(性别、年龄、eGFR、收缩压、Mayo影像分类和突变类型)的预测价值。
- 另在独立外部验证队列(N=144)中验证结果。
主要发现
- 平均随访5.0±2.3年期间,平均eGFR斜率为−3.46±2.5 ml/min per 1.73 m2 per year。
- 303例患者(50.8%)发生快速疾病进展(eGFR年下降≥3 ml/min per 1.73 m2)。
- 279例患者(46.8%)达到肾脏衰竭或eGFR下降30%的复合终点。
- 尿白蛋白/肌酐、尿MCP-1/肌酐和血清和肽素一致且独立预测eGFR斜率(均P < 0.001)。
- 快速进展预测的AUC从基线模型0.79(95%CI 0.76至0.85)升至包含MCP-1/肌酐和和肽素的0.83(95%CI 0.81至0.88),P=0.006。
关键数值与推荐
- 快速疾病进展定义为eGFR年下降≥3 ml/min per 1.73 m2。
- 复合肾脏终点定义为肾脏衰竭或eGFR下降30%。
临床怎么用
- 临床可考虑将尿白蛋白/肌酐、尿MCP-1/肌酐和血清和肽素纳入ADPKD风险分层以改善个体化预测。
- 这些生物标志物在早期疾病和MIC 1C患者中仍有预测价值,可用于传统工具难以判断的亚组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Risk prognostication in autosomal dominant polycystic kidney disease can be improved by combining clinical, genetic, and volumetric data. Various biomarkers have been explored in autosomal dominant polycystic kidney disease, but it is unclear which biomarkers are most suitable to integrate into risk stratification tools. Urinary albumin/creatinine, monocyte chemotactic protein-1/creatinine, and serum copeptin are independently associated with kidney outcomes, even in early disease and MIC 1C. BACKGROUND: Risk stratification tools for autosomal dominant polycystic kidney disease (ADPKD) predict kidney outcomes on a group level but lack precision in patients. METHODS: We assessed the value of adding 13 prognostic biomarkers to established risk factors (sex, age, eGFR, systolic BP, Mayo Imaging Classification [MIC], and mutation type) for predicting disease progression. We included 596 patients from the Developing Intervention Strategies to Halt Progression of ADPKD cohort with ≥2 eGFR measurements and ≥1-year follow-up. RESULTS: During a mean±SD follow-up of 5.0±2.3 years, the mean±SD eGFR slope was −3.46±2.5 ml/min per 1.73 m2 per year. Rapid disease progression (eGFR loss ≥3 ml/min per 1.73 m2 per year) occurred in 303 patients (50.8%), and 279 patients (46.8%) reached the combined end point of kidney failure or 30% eGFR decline. Urinary albumin/creatinine, urinary monocyte chemotactic protein-1/creatinine, and serum copeptin consistently and independently predicted eGFR slope (all P < 0.001), rapid disease progression (area under the curve increasing from 0.79 [95% confidence interval (CI), 0.76 to 0.85] for a baseline model to 0.83 [95% CI, 0.81 to 0.88] when monocyte chemotactic protein-1/creatinine and copeptin were included, P = 0.006), and reaching the combined kidney end point (C-index improving from 0.806 [95% CI, 0.78 to 0.84] for a baseline model to 0.82 [95% CI, 0.79 to 0.85] for a model also containing albumin/creatinine and copeptin, P < 0.001). These results were confirmed in an independent external validation cohort (N=144) and were robust in early disease stages and in patients with moderately increased kidney volumes (MIC 1C). CONCLUSIONS: Our findings suggest that incorporating these biomarkers into ADPKD risk stratification tools will improve risk prediction, even in subgroups where prognostication is most challenging and relevant.
引用
- Bais T, Knol MGE, Xue L, et al. Predicting Kidney Outcomes in Autosomal Dominant Polycystic Kidney Disease: A Comprehensive Biomarker Analysis. Clin J Am Soc Nephrol. 2025. PMID: 40067938. doi:10.2215/CJN.0000000680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。